Riluzole for motor neurone disease

BMJ

Volumn 322, Issue 7297, 2001, Pages 1305-

  Sandercock, Josie ^a   Burls, Amanda ^a   Hyde, Chris ^a   Fry Smith, Anne ^a   Barton, Pelham ^a   Bryan, Stirling ^a   Stewart, Antony ^b   Wheatley, Keith ^a   Gray, Richard ^a   Stewart, Robert ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE; NEUROPROTECTIVE AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; DOSE RESPONSE; EVIDENCE BASED MEDICINE; HUMAN; LETTER; MOTOR NEURON DISEASE; PRIORITY JOURNAL; SURVIVAL; UNITED KINGDOM; CLINICAL TRIAL; DRUG APPROVAL; NOTE;

CLINICAL TRIALS; DRUG APPROVAL; GREAT BRITAIN; HUMANS; MOTOR NEURON DISEASE; NEUROPROTECTIVE AGENTS; RILUZOLE;

EID: 0035954106     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.322.7297.1305     Document Type: Letter

References (13)

1. Stewart A, Sandercock J, Bryan S, Hyde C, Barton PM, Fry-Smith A, et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technology Assessment (in press).
2. Riluzole for motor neurone disease—HTA report part 1. www.nice.org.uk/pdf/Riluzole_htarep_part1.pdf; accessed 5 Feb 2001.
3. National Institute for Clinical Excellence. Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease. www.nice.org.uk/pdf/RILUZOLE_full_guidance.pdf; accessed 5 Feb 2001. (Technology appraisal guidance No 20.)
4. Kmietowicz Z. NICE approves drugs for Alzheimer's disease. BMJ 2001; 322: 190. (27 January.)
5. Committee for Proprietary Medicinal Products. European public assessment report (EPAR). Rilutek. London: European Agency for the Evaluation of Medicinal Products, 1999.
6. Kmietowicz Z. NICE approves drugs for Alzheimer's disease. BMJ 2001; 322: 190. (27 January.)
7. National Institute for Clinical Excellence. Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease. www.nice.org.uk/pdf/RILUZOLE_full_guidance.pdf; accessed 5 Feb 2001. (Technology appraisal guidance No 20.)
8. Stewart A, Sandercock J, Bryan S, Hyde C, Barton PM, Fry-Smith A, et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technology Assessment (in press).
9. Riluzole for motor neurone disease—HTA report part 1. www.nice.org.uk/pdf/Riluzole_htarep_part1.pdf; accessed 5 Feb 2001.
10. Kmietowicz Z. NICE approves drugs for Alzheimer's disease. BMJ 2001; 322: 190. (27 January.)
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939–944.
12. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. JAMA 1997; 277: 813–817.
13. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CDA. Ethnic differences in incidence of stroke: prospective study with stroke register. BMJ 1999; 318: 967–971